|One-year clinical outcome in an unselected patient population treated with the Genous™ endothelial progenitor cell capturing stent.|
|PMID: 20853436 Owner: NLM Status: MEDLINE|
|OBJECTIVE: We assessed the 1-year clinical outcome in a large cohort of unselected patients treated with an endothelial progenitor cell (EPC) capturing coronary stent.
BACKGROUND: The novel EPC capturing stent is coated with CD34+ antibodies that bind circulating EPCs to the stent surface, thereby accelerating endothelialization of the stent struts; it is hypothesized that this may prevent restenosis and stent thrombosis.
METHODS: A total of 405 unselected patients were treated percutaneously with the EPC capturing stent. The majority of patients had complex lesions with an estimated high risk of restenosis.
RESULTS: The primary endpoint defined as the composite of cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR) at 1-year was 13.3%, mainly attributable to TLR which was 10.9%. The occurrence of definite and probable ST was low, 0.5 and 0.7%, respectively. Based on the risk of restenosis, in patients with an estimated high risk of restenosis (n = 249), the composite primary endpoint was 16.1% versus 9.0% in patients with an estimated low risk (n = 155). Moreover, the 1 year clinical outcomes in diabetic patient compared well with the nondiabetic patients.
CONCLUSION: In this single-center study, the 1-year clinical follow-up in a "real-world" population treated with the EPC capturing stent showed good results. Currently, large randomized studies are conducted to evaluate the long-term safety and efficacy of this stent.
|Margo Klomp; Marcel A M Beijk; Jan G P Tijssen; Robbert J de Winter|
Related Documents :
|20568666 - Vertebral artery origin stents revisited: improved results with paclitaxel-eluting stents.
9852446 - Randomized trial of stent placed above and across the sphincter of oddi in malignant bi...
8001486 - Long-term experience in wallstent therapy for malignant choledochal stenosis.
20573476 - Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenti...
19453406 - Long-term effects of combined immunosuppressive treatment on myasthenic crisis.
11717716 - Invasive enteritis by strongyloides stercoralis presenting as acute abdominal distress ...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2011-03-09|
|Title: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions Volume: 77 ISSN: 1522-726X ISO Abbreviation: Catheter Cardiovasc Interv Publication Date: 2011 May|
|Created Date: 2011-04-26 Completed Date: 2011-08-15 Revised Date: 2014-07-30|
Medline Journal Info:
|Nlm Unique ID: 100884139 Medline TA: Catheter Cardiovasc Interv Country: United States|
|Languages: eng Pagination: 809-17 Citation Subset: IM|
|Copyright © 2011 Wiley-Liss, Inc.|
|APA/MLA Format Download EndNote Download BibTex|
Angioplasty, Balloon, Coronary / adverse effects, instrumentation*, mortality
Antigens, CD34 / metabolism
Coated Materials, Biocompatible*
Coronary Restenosis / etiology, prevention & control
Coronary Stenosis / immunology, mortality, pathology, radiography, therapy*
Diabetes Mellitus / mortality, pathology
Endothelial Cells / immunology, pathology*
Myocardial Infarction / etiology, prevention & control
Practice Guidelines as Topic
Stem Cells / immunology, pathology*
Thrombosis / etiology, prevention & control
|0/Antigens, CD34; 0/Coated Materials, Biocompatible; 0/Metals|
|Catheter Cardiovasc Interv. 2011 May 1;77(6):818-9
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Entomotoxic action of Sambucus nigra agglutinin I in Acyrthosiphon pisum aphids and Spodoptera exigu...
Next Document: Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination.